News stories about BiondVax Pharmaceuticals (NASDAQ:BVXV) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BiondVax Pharmaceuticals earned a news impact score of 0.05 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.7150022817144 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, ValuEngine lowered shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday.
Shares of BiondVax Pharmaceuticals (NASDAQ BVXV) traded down $0.09 during trading on Tuesday, reaching $5.42. 9,700 shares of the company’s stock were exchanged, compared to its average volume of 44,997. BiondVax Pharmaceuticals has a twelve month low of $3.04 and a twelve month high of $10.75.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact BiondVax Pharmaceuticals (BVXV) Share Price” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/05/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-biondvax-pharmaceuticals-bvxv-share-price.html.
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
What are top analysts saying about BiondVax Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BiondVax Pharmaceuticals Ltd. and related companies.